Treo 500+50 mg brusetabletter Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

treo 500+50 mg brusetabletter

viatris aps - acetylsalicylsyre, caffein - brusetabletter - 500+50 mg

Onglyza Den Europæiske Union - dansk - EMA (European Medicines Agency)

onglyza

astrazeneca ab - saxagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

Bydureon Den Europæiske Union - dansk - EMA (European Medicines Agency)

bydureon

astrazeneca ab - exenatid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - bydureon er angivet i voksne over 18 år og ældre med type 2-diabetes mellitus til forbedring af glykæmisk kontrol i kombination med andre glukose sænkende lægemidler, når behandlingen er i brug, sammen med diæt og motion ikke giver tilstrækkelig glykæmisk kontrol (se afsnit 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer). bydureon er indiceret til behandling af type 2-diabetes mellitus i kombination med:metforminsulphonylureathiazolidinedionemetformin og sulphonylureametformin og thiazolidinedionein voksne, som ikke har opnået tilstrækkelig glykæmisk kontrol på maksimalt tolereret dosis af disse mundtlige behandlinger.

Delstrigo Den Europæiske Union - dansk - EMA (European Medicines Agency)

delstrigo

merck sharp & dohme b.v. - doravirine, lamivudin, er tenofovir disoproxil fumarate - hiv infektioner - antivirale midler til behandling af hiv-infektioner, kombinationer - delstrigo er indiceret til behandling af voksne, som er smittet med hiv-1 uden tidligere eller nuværende bevis for modstand, nnrti klasse, lamivudin, eller tenofovir. delstrigo is also indicated for the treatment of adolescents aged 12 years and older weighing at least 35 kg who are infected with hiv-1 without past or present evidence of resistance to the nnrti class, lamivudine, or tenofovir and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil.

Pifeltro Den Europæiske Union - dansk - EMA (European Medicines Agency)

pifeltro

merck sharp & dohme b.v. - doravirine - hiv infektioner - antivirale midler til systemisk anvendelse - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.